

CZECH REPUBLIC

Recent and planned developments in pharmaceutical policies 2014

Policies related to high cost medicines

D E V E L O P M E N T S	Changes in pricing	Changes in reimbursement
	<ul style="list-style-type: none"> No relevant system changes in 2014 01/01/2015: Decrease of VAT rate on medicines from 15% to 10% (will affect retail price automatically) 	<ul style="list-style-type: none"> No relevant system changes in 2014 Ongoing 2nd wave of reimbursement reviews 01/01/2015: Decrease of VAT rate on medicines from 15% to 10% (will affect reimbursement price automatically)
	Other changes	
	<ul style="list-style-type: none"> 01/01/2014: Hospital stay fee cancelled (was approx. €3.6 per day). Plans on cancelation of other fees (dispensing fee, clinical examination fee, currently approx. €1.1). 	
S P E C I A L T O P I C	High cost medicines	
	<ul style="list-style-type: none"> <u>Special pricing policies:</u> There are no specific pricing policies for <u>high cost</u> medicines but there are special procedures for <u>highly innovative</u> medicines (which are usually expensive at the same time). ERP procedure is used but with some alleviation (2 country references are required at minimum instead of regular 3). <u>Special reimbursement/funding policies:</u> There are no specific pricing policies for <u>high cost</u> medicines but there are special procedures for <u>highly innovative</u> medicines (which are usually expensive at the same time). Temporary reimbursement for 2+1 years is granted if the product is reimbursed in 2 reference basket countries at minimum. The MAH must establish a register and provide evidence and CEA to be able to acquire 3rd year temporary reimbursement. Agreement with the insurance funds on budget limitation is also a prerequisite. <u>High cost medicines at the interface of out-patient and in-patient sectors:</u> The <u>highly innovative</u> medicines are provided based on agreements with the insurance funds in the out-patient sector. Similar situation is in the in-patient sector although the reimbursement price is not decided by SÚKL. <u>Key challenges and solutions:</u> New High cost medicines with enormous budget impact (huge number of potential patients). 	